The proto-oncogene BRAF (v-Raf murine sarcoma viral gene homolog B1) is a well-known component of the MEK/ MAPK pathway that plays a critical role in cell growth. This component was first demonstrated elegantly and comprehensively by Davies et al 1 in 2002 . Mutations in BRAF have been identified in numerous malignant neoplasms including melanoma, papillary thyroid carcinoma, colorectal carcinoma, non-small cell lung cancer, and hairy cell leukemia. [1] [2] [3] [4] [5] Moreover, these mutations are increasingly recognized for their diagnostic, prognostic, and therapeutic implications. A BRAF V600E (c.1799T>A) mutation has a positive predictive value for papillary thyroid carcinoma that may approach 100% 6, 7 and likely is associated with local recurrence and poor clinical outcomes. 8, 9 Mutated BRAF blunts the response to antiepidermal growth factor receptor therapy in patients with metastatic colorectal adenocarcinoma. 10 Furthermore, BRAF mutations may be targetable; the BRAF inhibitor vemurafenib was recently approved by the Food and Drug Administration (FDA) for unresectable or metastatic melanoma. Its indications are limited to tumors harboring the activating BRAF V600E (c.1799T>A) mutation. A new drug application for a second drug, dabrafenib, has also been submitted for the treatment of V600E-bearing melanoma.
Given the significance of BRAF mutations in diagnosis and clinical management, the reporting of BRAF mutational status of papillary thyroid carcinoma, lung and colorectal adenocarcinoma, and malignant melanoma has become routine pathology practice. Although V600E (c.1799T>A) represents approximately 95.9% of all BRAF mutations, other mutations are occasionally encountered. For example, V600E (c.1799_1800delTGinsAA) accounts for approximately 74% of non-V600E (c.1799T>A) BRAF mutations in malignant melanoma, whereas V600K (c.1798_1799delGTinsAA) represents 20%, and other mutations comprise approximately 6%. 11 Moreover, different BRAF mutations appear to be associated with unique clinicopathologic features. 12, 13 Thus, an ideal BRAF assay should be able to detect non-V600E (c.1799T>A) mutations, and these specific BRAF base changes should be reported rather than merely stating the presence or absence of a BRAF mutation.
Pyrosequencing is commonly used to detect BRAF mutations. 14 Compared with Sanger sequencing, pyrosequencing is inherently more quantitative, has a superior limit of detection (5% minor allele frequency), and is faster. [15] [16] [17] However, pyrograms of complex mutations can generate confusing patterns that are often difficult to resolve without further investigation. To assist in the resolution of complex pyrograms, we recently developed a freely available software program, Pyromaker (http://pyromaker.pathology.jhmi.edu), which generates simulated traces for pyrosequencing results based on user inputs. 18 Although Pyromaker is useful in the iterative hypothesis testing of solutions for complex pyrosequencing results, our first validation 18 dealt primarily with complex KRAS mutations with pyrograms that involved three or four peak differences. By contrast, complex BRAF mutations commonly produce pyrograms with more than twice that number of peak differences, so even the process of hypothesis generation can be challenging.
In this study, we introduce the use of Pyromaker to make a lookup table for all known mutations of the sequenced region detected with a dispensation sequence. We show that the use of a lookup table followed by a confirmatory virtual trace comparison leads to rapid and unambiguous identification of all known BRAF mutations in the region of interest. Furthermore, we show that the lookup table facilitates a critical evaluation and rational choice of the dispensation sequence used in mutational analysis.
Materials and Methods

Pyromaker
The general features and specifications of Pyromaker have been previously described. 18 The application of Pyromaker in the current study differed in two ways from the previous publication. First, peak magnitudes of the pyrogram were exported to obtain the positions in the pyrogram for which the mutant sequence differed from the wild-type sequence. Second, annotations of these differences were added automatically to the virtual pyrogram. These features were made available in an update to the freely available public version (http://pyromaker.pathology.jhmi.edu). Using these modifications, Pyromaker generated a list of altered peaks for all of the relevant mutations recorded in the Catalogue of Somatic Mutations in Cancer (COSMIC) at the Sanger Institute (Cambridge, England; http://www.sanger.ac.uk/ genetics/CGP/cosmic, last accessed November 12, 2012) and all hypothetical single-point mutations for codon 600. All virtual pyrograms were plotted assuming a heterozygous mutant allele and a 100% tumor cellularity so that the signal from the mutant DNA comprised 50% of the total signal. For comparison with the clinical pyrograms, the homebrew dispensation sequence, which was developed for mutations from BRAF codons 596 to 605, was GTAGCTAGCTAT-CAGCATCGACTCTCGATGAGTG, where the nucleotide triphosphates are simply listed as single characters in the preceding sequence. For the analysis of the kit-based dispensation sequence available from Qiagen (Valencia, CA), the reverse dispensation sequence TCGTATCTGTAG was used. In virtual pyrograms, as in actual pyrograms, a position refers to one deoxyribonucleotide triphosphate (dNTP) injection ("dispensation") on the x axis.
Sample Preparation and DNA Extraction
BRAF mutations were detected in the clinical molecular laboratory during routine analysis. The V600_K601delinsE (c.1799_1801delTGA) was found in primary papillary thyroid carcinoma, and the classic V600E (c.1799T>A) was found in primary malignant melanoma. All other mutations were found in specimens with metastatic melanoma. After H&E-stained slide review and tumor tissue selection, the corresponding tissue from five unstained, 5-μm-thick tissue sections was manually microdissected using Pinpoint reagents according to the manufacturer's protocol (ZymoResearch, Orange, CA). DNA was purified from the sample using the QIAmp DNA kit (Qiagen) and quantified by OD 260 nm. To ensure the appropriate sensitivity of the homebrew dispensation sequence, the peak height of the mutant peak corresponding to c.1799T>A was measured with the methods involving the kit-based and homebrew dispensation sequences. The BRAF mutation status of the BRAF-mutated RKO cell line was tested with each method undiluted and at dilutions of 1:1, 1:2, 1:5, 1:10, 1:20, and 1:100 to BRAF wild-type DNA. This validation is shown in ❚Supplemental 
Pyrosequencing
Samples were amplified using polymerase chain reaction (PCR) in a 25-μL reaction containing 0.2 μmol/L forward primer (5′-GAAGACCTCACAGTAAAAATAG-3′), 0.2 μmol/L reverse primer (5′-biotin~ATAGCCTCAATTC-TTACCATCC-3′), 0.16 μL HotStarTaq DNA polymerase (Qiagen), 0.15 mmol/L magnesium chloride (Qiagen), 0.15 mmol/L dNTPs (Applied Biosystems, Foster City, CA), and 2.5 μL PCR buffer (Qiagen). Samples were amplified in a Veriti thermal cycler (Applied Biosystems) with the following conditions: 95°C for 15 minutes, 42 cycles (95°C for 20 seconds, 53°C for 30 seconds, and 72°C for 20 seconds), and 72°C for 5 minutes. The amplicons were sequenced using PyroMark Gold reagents (Qiagen) on a PyroMark Q24 instrument (Qiagen). The sequencing reagents contained 0.3 μmol/L sequencing primer (5′-GACCTCACAG-TAAAAATAGGTGATTTTG-3′) and annealing buffer. The nucleotide dispensation order used for codons 596 to 606 was GTAGCTAGCTATCAGCATCGACTCTCGATGAGTG.
Sanger Sequencing
Samples were PCR amplified using the same conditions as those used for pyrosequencing but using M13-tailed primers with the following sequences: 5′-M13F-TTCTTCAT-GAAGACCTCACAG-3′ (forward) and 5′-M13R-GTG-GAAAAATAGCCTCAATTCTTAC-3′ (reverse). Amplicons were purified using ExoStar (GE Healthcare, Piscataway, NJ) and sequenced using BigDye v3.1 reagents (Applied Biosystems). Sequencing products were purified with BigDye XTerminator reagents (Applied Biosystems), and bidirectional sequencing was performed on an ABI 3500xl (Applied Biosystems) capillary electrophoresis instrument.
Results
All Known BRAF Mutations Produce Distinct Pyrograms With the Homebrew Dispensation Sequence
We identified all known mutations in the BRAF oncogene in COSMIC and produced the expected pyrosequencing traces using Pyromaker, inputting either our homebrew dispensation sequence or the dispensation suggested in the Qiagen BRAF pyrosequencing kit. The homebrew dispensation has the advantages that (1) the sequence is the forward sequence, (2) the 1× peak height is well defined before sequencing through the V600 region, and (3) it can detect rare mutations down-and upstream from the V600 codon. We then tabulated all the peaks that were at new positions or at existing positions where the peak was either increased or decreased. The expected peak changes for all known BRAF mutations gave distinct patterns with the homebrew dispensation sequence. ❚Table 1❚ lists all the activating BRAF mutations and the mutations discussed here [19] [20] [21] [22] [23] [24] [25] ; the complete list is shown in ❚Supplemental is manifest only as a reduction of G activity and increase in T activity. With BRAF, these are only seen in the relatively rare mutations c.A1791G, c.G1792A, and c.C1793T shown in ❚Supplemental Figure 1A❚ , ❚Supplemental Figure 1B❚ , and ❚Supplemental Figure 1C❚ , respectively.
Virtual pyrograms for each of the mutations listed in Table  1 are shown in Supplemental Figure 1 , ❚Supplemental Figure  2❚ , and ❚Supplemental Figure 3❚ . Peak-change combinations alone were inadequate to resolve all mutations. Two combinations, the change of positions 7 and 8 ❚Supplemental Figure  4A❚ and the change of positions 20 and 21, had ambiguities that required information about whether the peak magnitude had increased or decreased ❚Supplemental Figure 4B❚ to definitively define them. For example, the L597L (c.1791A>G) mutation leads to a decrease in signal at the seventh position (A) and an equivalent increase in the eighth position (G), whereas the A598T (c.1792G>A) mutation produces opposite changes ❚Supplemental Figure 4D❚ . The change in direction was useful in the more complex combination of peaks produced by both V600_S605delinsD (c.1799_1814delinsA) and V600_S605delinsEK (c.1799_1815delinsAAAAG) ❚Supple-mental Figure 4C❚ and ❚Supplemental Figure 4F❚ . In this case, the direction of change in the 20th position-decreased for V600_S605delinsD (c.1799_1814delinsA) and increased for V600_S605delinsEK (c.1799_1815delinsAAAAG)-led to the correct distinction between these two pyrograms.
Use of the Kit Dispensation Sequence
Applying the kit-based dispensation sequence, the expected peak changes for all known BRAF mutations in the sequencing region of the homebrew dispensation sequence are shown in Table 1 . The reverse (antisense) sequence was used for the analysis because that is the sequencing direction used by the kit-based approach. All three degenerate sets have peak changes in exactly the same directions. Two of the three degenerate pyrograms show peak changes that were resolved unambiguously with peak ratios. The ratio of change in the second and fourth positions was 0.5 for the V600R (c.1798_1799delGTinsAG) mutation and 2.0 for the V600G (c.1799T>G) mutation ❚Supplemental Figure 5A❚ and ❚Supplemental Figure 5E❚ . Similarly, the ratio of change in the fourth and fifth positions was 1.0 for the insertion of TAC after codon 599 and 2.0 for the V600K (c.1798_1799delGTinsAA) mutation ❚Supplemental Figure 5B❚ and ❚Supplemental Figure  5F❚ . One degenerate set could not be resolved using the kitbased dispensation sequence; the A598V (c.1793C>T) and A598_T599insV (c.1794_1795insGTT) mutations produced identical pyrograms because the insertion of GTT disrupted the final positions in the kit dispensation sequence ❚Supple-mental Figure 5C❚ and ❚Supplemental Figure 5G❚ . Virtual pyrograms showed that extending the kit-based dispensation sequence by C and G or C and T injections would resolve this degeneracy as the polymerase would advance first to the C in either case and then to a G in the case of the insertion or to a T in the case of the substitution ❚Supplemental Figure 5D❚ 
Resolving Simple and Complex BRAF Pyrograms With a Lookup Table
Applying the findings of Table 1 to the clinical pyrograms seen in ❚Figure 1❚, usual and unusual BRAF mutations were identified unambiguously with the pyrosequencing results alone. In cases A and B, the single and double substitution had only two peak changes, which were identified with minimal effort. Cases C and D had seven and eight peak changes, respectively. The affected peak positions were unique to those two mutations. As such, they were identified as V600K (c.1798_1799delGTinsAA) and V600R Resolving V600E (c.1798_1799delGTinsAA) and V600_ K601delinsE (c.1799_1801delTGA)
The clinical pyrograms shown in ❚Figure 3A❚ and ❚Fig-ure 3B❚ involve the same peaks, all of which were changed from the wild-type pyrogram in the same direction. Using the lookup table from Table 1 , it was evident that the mutations (c.1798_1799delGTinsAG) with the same lookup operation used in the simpler cases. The mutations were confirmed with a virtual pyrogram that matched the clinical pyrograms exactly. The unusual BRAF mutant sequences were additionally confirmed with Sanger sequencing ❚Figure 2B❚, ❚Figure 2C❚, and ❚Figure 2D❚. was made. The mutations that were combined were chosen because they involved positions 17, 20, and 21. The table can be found in ❚Supplemental Table 3❚ . The only solution that matched this peak-change combination was V600_K601delinsEI (c.1799_1802delTGAAinsAAAT). The V600E (c.1799_1800delTGinsAA) and K601I (c.1802A>T) were determined to be on the same strand of mutant DNA because a combination of two mutant populations could not cause the marked increase in the A peak at position 17 even if the maximum amount of tumor harbored the V600E (c.1799_1800delTGinsAA) mutation (data not shown). The V600_K601delinsEI (c.1799_1802delTGAAinsAAAT) mutation was confirmed with Sanger sequencing and shown in ❚Figure 2F❚.
Discussion
The Virtual Pyrogram Lookup Table
Simple lookup tables such as the one described herein are suitable for problems involving small searches of limited were clearly either V600E (c.1799_1800delTGinsAA) or V600_K601delinsE (c.1799_1801delTGA). This ambiguity was resolved with Pyromaker-generated plots of the virtual pyrograms, shown below the clinical pyrograms in Figure 3 . As seen in the virtual pyrograms, the first two altered peaksin positions 17 and 19-were altered at different ratios. In the case of V600E (c.1799_1800delTGinsAA), these peaks occurred with a ratio of 5.5, whereas in V600_K601delinsE (c.1799_1801delTGA), the same peaks occurred with a ratio of 2.2. Because both peaks are caused by sequencing of the mutant and not the wild-type DNA, the ratio between them was independent of zygosity and tumor-cell composition. The V600E (c.1799_1800delTGinsAA) mutation was confirmed using Sanger sequencing and shown in ❚Figure 2E❚.
Hypothesis-Based Pattern Matching of a New Mutation
The lookup table in Table 1 failed to identify the mutation in the clinical pyrogram ❚Figure 4A❚; there was no mutation with changes at positions 17, 20, and 21 because this mutation is novel and not previously reported in COSMIC. A lookup table of combinations of mutations
❚Figure 2❚ Sanger confirmation for A, wild BRAF Sanger trace; B, V600D (c.1798_1800delGTGinsGAT); C, V600K (c.1798_1799delGTinsAA); D, V600_K601delinsEI (c. 1799_1802delTGAAinsAAAT); E, homozygous V600R (c.1798_1799delGTinsAG); and F, V600E (c.1799_1800delTGinsAA). 26 and in peptide sequencing. 27 When nonexact matching is introduced, the applications become even different stations in the dispensation sequence or by confirming that changes in the direction or ratio between peaks in degenerate pyrograms occur in a reproducible and dependable manner.
If an assay is robust to detect mutations in a well-characterized gene, it is plausible to envision automating the lookup table approach for in silico assignment of the mutation status, and this is ultimately the goal for increasingly multiplexed molecular assays. However, such an approach will involve several technical and regulatory complications. These complications include the need to normalize the pyrogram signal; standardize the representation of the pyrogram for automated pattern matching; validate the process and institute proficiency testing of automated pattern matching for molecular results, especially to account for low-signal mutations; and institute commensurate billing and reimbursement changes. Although the approach presented here is a necessary advancement toward automated analysis, it is not currently sufficient to use this approach in this way.
Superiority of the Homebrew Dispensation Sequence
The results presented herein demonstrate how the homebrew dispensation sequence enables the unambiguous identification of all known BRAF mutations from codon 596 to 605, whereas the less exhaustive kit-based dispensation sequence is shown to miss all mutations upstream to codon 598 and gives an unresolvable result for two mutations at codon 598. In addition, because the 1801 nucleotide is upstream from the sequencing region of the kit-based assay, it may not sequence the V600_K601delinsE (c.1799_1801delTGA) mutation. This is a known activating mutation, so failure to recognize it could lead to underuse of the targeted BRAF inhibitor therapy. The significance of this particular mutation should be evaluated in each specific laboratory; the key finding is that the lookup table method presented herein predicts assay performance and enables a rational method for choosing an ideal dispensation sequence based on the needs of a particular molecular laboratory. In our practice setting, the need for detecting all known BRAF mutations leads to the choice of the homebrew assay.
In summary, the virtual pyrogram is a useful tool for confirming hypothetical solutions to pyrosequencing results. Sequencing regions, such as BRAF codons 596 to 605, can produce pyrograms in which the starting point for iterative hypothesis testing is difficult to appreciate. Therefore, the lookup table of peak changes comprises a helpful adjunct to hypothesis testing. Because of the possibility of degeneracies, lookup more abundant and have been widely used in the analytical chemistry laboratory to identify small molecules based on fragmentation patterns 28 and to accurately characterize protein classes in tissues. 29, 30 Genetic data analysis frequently involves matching small searches against very large data sets, so the problem space becomes so large that matching to a table is inefficient. Lookups in those settings are implemented as exact matching in sophisticated suffix trees, such as those used in efficient linear matching. 31 Although more elaborate algorithms have applications in larger problems in molecular genetics, the interpretation of the clinical pyrogram is limited to specific genes and interpretation by a molecular pathologist. Thus, the approach presented herein is the ideal match of sophistication for practical molecular pathology workflows.
Necessity of the Virtual Pyrogram Lookup Table
We previously demonstrated the use of virtual pyrograms as a useful tool in iterative problem solving when complex pyrosequencing is difficult to interpret. 18 Our previous study focused primarily with KRAS mutations in codons 12 and 13, and the most complex result involved peak changes at only four dispensation positions. As such, a human could iterate through hypothetical solutions to the correct mutation with little effort, and the starting solutions were chosen easily based on the small number of changed pyrogram peaks. By contrast, the results presented here demonstrate multiple peak changes. Although the previously described pathologistguided approach to solving pyrograms is still valid, a de novo starting point for numerous peak changes requires significant effort. To address this issue, we now present a novel pyrosequencing analysis approach that uses a lookup table to expedite the first-and usually the correct-hypothesis. For currently known BRAF mutations, the pyrosequencing results resolve the mutations unambiguously. However, exhaustive testing of every imaginable mutation is not computationally feasible in the clinical setting, so there remains a possibility that unusual pyrograms may match the lookup table yet represent either a degenerate solution or a new mutation that is degenerate with one already described. Thus, the lookup table solution must be followed with a confirmatory virtual pyrogram comparison to ensure that the solution yields the correct peak proportions and directions.
Scalability of the Virtual Pyrogram Lookup Table
Although the results are centered on BRAF pyrogram interpretation, the same approach could be applied to any clinical pyrosequencing assay. In fact, generating a lookup table for expected mutations is most desirable in the validation stage of assay development because dissimilar mutations can produce similar pyrograms. In the development of a rugged assay, increased resolution can often be gained by adding
